Combination pharmacotherapy for cardiovascular disease prevention: Threat or opportunity for public health?

American Journal of Preventive Medicine

Volumn 29, Issue 5 SUPPL. 1, 2005, Pages 134-138

  Narayan, K M Venkat ^a   Mensah, George A ^a   Sorensen, Stephen ^a   Cheng, Yiling J ^a   Vinicor, Frank ^a   Engelgau, Michael M ^a   Williamson, David F ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLYPILL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; HUMAN; ISCHEMIC HEART DISEASE; PREVENTIVE MEDICINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; SYMPTOM;

CARDIOVASCULAR DISEASES; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; PUBLIC HEALTH; UNITED STATES;

EID: 29644434668     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2005.07.022     Document Type: Review

References (14)

1. National Center for Chronic Disease and Health Promotion, Centers for Disease Control and Prevention. Preventing heart disease and stroke. Available at: www.cdc.gov/nccdphp/bb_heartdisease/index.htm.
2. P. Greenland, M.D. Knoll, J. Stamler Major risk factors as antecendents of fatal and nonfatal coronary heart disease events JAMA 290 2003 891 897
3. D.G. Hackman, S.S. Anand Emerging risk factors for atherosclerotic vascular disease a critical review of the evidence JAMA 209 2003 932 940
4. A.D. Pradhan, P.J. Skerrett, J.E. Manson Obesity, diabetes, and coronary risk in women J Cardiovasc Risk 9 2002 323 330
5. N.J. Wald, M.R. Law A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419 1422
6. M.R. Law, N.J. Wald, J.K. Morris, R.E. Jordan Value of low dose combination treatment with blood pressure lowering drugs analysis of 354 randomized trials BMJ 326 2003 1427 1435
7. M.R. Law, N.J. Wald, A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke systematic review and meta-analysis BMJ 326 2003 1423 1426
8. A. Rogers A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries BMJ 326 2003 1407 1408 (editorial)
9. R. Smith The most important BMJ for 50 years? BMJ 326 2003 0 (editors' choice).
10. R. Smith Polypill may be available in two years BMJ 326 2003 0
11. D.M. Black, S.L. Greenspan, K.E. Ensrud The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
12. P. Gaede, P. Vedel, N. Larsen, G.V.H. Jensen, H.H. Parving, O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
13. S.H. Saydah, J. Fradkin, C.C. Cowie Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes JAMA 291 2004 335 342
14. G. Rose Sick individuals and sick populations Int J Epidemiol 30 2001 427 432